) Attempts have been made over the last several years to develop vaccines that would aid in the eradication of human malignancy. In general, these vaccines have not been effective. Recent advances in both basic immunology and molecular biology have demanded a re-evaluation of cancer vaccines. We now know that human tumors are immunogenic and have defined specific tumor antigens. Furthermore, we have a more detailed understanding of how T-cells recognize antigens, as peptide fragments presented in human MHC molecules. Finally, we have a better understanding of how tumors evade immune recognition, including the generation of antigen negative variants by an immune response that actually eradicated antigen bearing tumor cells. The development of antigen negative variants underscores the need for vaccines targeting multiple important antigens at a minimal disease state. This proposal will allow the identification and assessment of multiple potential antigens as candidates for a polyvalent vaccine with the 5-year goal of initiating a Phase I studies of a multiple antigen vaccines to evaluate the ability to generate immunity to multiple cancer causing proteins. The focus of my group is to develop cancer vaccines targeting breast, ovarian, prostate, and colon cancer for the prevention of cancer relapse.
The specific aims of this proposal are: (1) to determine whether pre-existing antigen specific cellular and humoral immune responses occur in patients with cancer bearing the candidate antigen as compared to a normal control population, (2) to determine the most effective vaccination strategy for augmenting existent immunity to a candidate antigen, in vivo, to potentially therapeutic levels, (3) to identify novel immunogenic proteins present in solid tumors that may serve as candidate antigens in the development of cancer vaccines, and (4) to determine in a series of limited Phase I clinical trials, whether a vaccine constructed of peptide epitopes or the DNA of a candidate antigen can elicit antigen specific immunity in patients with cancer bearing that antigen.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA085218-05
Application #
6769569
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
2000-07-05
Project End
2005-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
5
Fiscal Year
2004
Total Cost
$119,903
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Dang, Yushe; Wagner, Wolfgang M; Gad, Ekram et al. (2012) Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 18:3122-31
Lu, Hailing; Wagner, Wolfgang M; Gad, Ekram et al. (2010) Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 184:5360-7
Olson, Brian M; Frye, Thomas P; Johnson, Laura E et al. (2010) HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 59:943-53
Goodell, Vivian; Waisman, James; Salazar, Lupe G et al. (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449-54
Goodell, Vivian; McNeel, Douglas; Disis, Mary L (2008) His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 9:23
Salazar, Lupe G; Coveler, Andrew L; Swensen, Ron E et al. (2007) Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 125:275-80
Goodell, Vivian; dela Rosa, Corazon; Slota, Meredith et al. (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 8:21
Dang, Yushe; Knutson, Keith L; Goodell, Vivian et al. (2007) Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 13:1883-91
Zhang, Hongtao; Knutson, Keith L; Hellstrom, Karl Erik et al. (2006) Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther 5:149-55
Goodell, Vivian; Salazar, Lupe G; Urban, Nicole et al. (2006) Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 24:762-8

Showing the most recent 10 out of 33 publications